Camrelizumab plus chemo for unresectable gallbladder cancer
Part of Cancer clinical trials.
This trial tests a combination of the immunotherapy drug camrelizumab with two chemotherapy drugs (gemcitabine and oxaliplatin, known as GEMOX) for people with gallbladder cancer that cannot be surgically removed. It aims to see if this treatment can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your gallbladder cancer cannot be removed by surgery, and it must be confirmed by a biopsy or finding cancer cells in bile.
- You have never had chemotherapy or immunotherapy for this cancer.
- You are in good enough health to do daily activities (ECOG score 0 or 1).
- Your blood counts and organ function (liver, kidneys, thyroid) meet safe levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a “before-surgery” (preoperative) treatment approach for gallbladder cancer that cannot be fully removed with an operation. It may help shrink or control the cancer and improve outcomes, especially if standard options have limits for you.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This Phase 2 trial tests a targeted treatment (GEMOX) given after gallbladder cancer surgery. It uses a blood test that looks for cancer-related DNA to monitor recurrence and guide care, aiming to improve outcomes for people with higher-risk disease.
This trial tests a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with two immunotherapy drugs (iparomlimab and tuvorilimab) for people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink the cancer or slow its growth.
Hear when a new Unresectable Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.